Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration.

Ward Y, Lake R, Faraji F, Sperger J, Martin P, Gilliard C, Ku KP, Rodems T, Niles D, Tillman H, Yin J, Hunter K, Sowalsky AG, Lang J, Kelly K.

Cell Rep. 2018 Apr 17;23(3):808-822. doi: 10.1016/j.celrep.2018.03.092.

PMID:
29669286
2.

Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.

Gillard M, Lack J, Pontier A, Gandla D, Hatcher D, Sowalsky AG, Rodriguez-Nieves J, Vander Griend D, Paner G, VanderWeele D.

Eur Urol Focus. 2017 Dec 8. pii: S2405-4569(17)30272-9. doi: 10.1016/j.euf.2017.12.003. [Epub ahead of print]

3.

PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.

VanderWeele DJ, Turkbey B, Sowalsky AG.

Expert Rev Precis Med Drug Dev. 2016;1(6):505-515. doi: 10.1080/23808993.2016.1267562. Epub 2016 Dec 12.

4.

Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.

Sowalsky AG, Kissick HT, Gerrin SJ, Schaefer RJ, Xia Z, Russo JW, Arredouani MS, Bubley GJ, Sanda MG, Li W, Ye H, Balk SP.

Clin Cancer Res. 2017 Jul 15;23(14):3823-3833. doi: 10.1158/1078-0432.CCR-16-2414. Epub 2017 Jan 24.

PMID:
28119368
5.

Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma.

Gerrin SJ, Sowalsky AG, Balk SP, Ye H.

Prostate. 2016 Sep;76(13):1227-36. doi: 10.1002/pros.23212. Epub 2016 Jun 8.

6.

SOX9 drives WNT pathway activation in prostate cancer.

Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, Balk SP, Yuan X.

J Clin Invest. 2016 May 2;126(5):1745-58. doi: 10.1172/JCI78815. Epub 2016 Apr 4.

7.

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.

Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C.

Clin Cancer Res. 2016 Jul 15;22(14):3672-82. doi: 10.1158/1078-0432.CCR-15-2309. Epub 2016 Mar 2.

8.

Reciprocal regulation of Abl kinase by Crk Y251 and Abi1 controls invasive phenotypes in glioblastoma.

Kumar S, Lu B, Dixit U, Hossain S, Liu Y, Li J, Hornbeck P, Zheng W, Sowalsky AG, Kotula L, Birge RB.

Oncotarget. 2015 Nov 10;6(35):37792-807. doi: 10.18632/oncotarget.6096.

9.

Loss of Wave1 gene defines a subtype of lethal prostate cancer.

Sowalsky AG, Sager R, Schaefer RJ, Bratslavsky G, Pandolfi PP, Balk SP, Kotula L.

Oncotarget. 2015 May 20;6(14):12383-91.

10.

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.

Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME.

Clin Cancer Res. 2015 Mar 15;21(6):1273-80. doi: 10.1158/1078-0432.CCR-14-1220. Epub 2014 Oct 15.

11.

Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer.

Sowalsky AG, Xia Z, Wang L, Zhao H, Chen S, Bubley GJ, Balk SP, Li W.

Mol Cancer Res. 2015 Jan;13(1):98-106. doi: 10.1158/1541-7786.MCR-14-0273. Epub 2014 Sep 4.

12.

Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.

Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP.

Clin Cancer Res. 2014 Mar 15;20(6):1590-600. doi: 10.1158/1078-0432.CCR-13-1863. Epub 2014 Jan 21.

13.

ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.

Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X.

J Clin Invest. 2013 Mar;123(3):1109-22. doi: 10.1172/JCI66666. Epub 2013 Feb 15.

14.

Clonal progression of prostate cancers from Gleason grade 3 to grade 4.

Sowalsky AG, Ye H, Bubley GJ, Balk SP.

Cancer Res. 2013 Feb 1;73(3):1050-5. doi: 10.1158/0008-5472.CAN-12-2799. Epub 2012 Nov 30.

15.

Suppression of E-cadherin function drives the early stages of Ras-induced squamous cell carcinoma through upregulation of FAK and Src.

Alt-Holland A, Sowalsky AG, Szwec-Levin Y, Shamis Y, Hatch H, Feig LA, Garlick JA.

J Invest Dermatol. 2011 Nov;131(11):2306-15. doi: 10.1038/jid.2011.188. Epub 2011 Jun 30.

16.

RalA function in dermal fibroblasts is required for the progression of squamous cell carcinoma of the skin.

Sowalsky AG, Alt-Holland A, Shamis Y, Garlick JA, Feig LA.

Cancer Res. 2011 Feb 1;71(3):758-67. doi: 10.1158/0008-5472.CAN-10-2756. Epub 2010 Dec 15.

17.

RalA suppresses early stages of Ras-induced squamous cell carcinoma progression.

Sowalsky AG, Alt-Holland A, Shamis Y, Garlick JA, Feig LA.

Oncogene. 2010 Jan 7;29(1):45-55. doi: 10.1038/onc.2009.307. Epub 2009 Oct 5.

Supplemental Content

Loading ...
Support Center